Insmed (INSM) announced that it intends to offer and sell $650M of shares of its common stock in an underwritten public offering. Goldman Sachs & Co. and Leerink Partners are acting as joint book-running managers for the offering.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on INSM:
- Insmed price target raised to $106 from $99 at RBC Capital
- Insmed price target raised to $102 from $90 at Morgan Stanley
- Mizuho ups Insmed target on ‘grand slam’ PAH data
- Buy Rating on Insmed Driven by Promising Phase 2 Results and Strategic Phase 3 Approach for PAH Treatment
- Insmed price target raised to $109 from $94 at BofA